Blood component therapy for cancer patients

Use of red blood cells older than five days for neonatal transfusion.

Journal of perinatology : official journal of the California Perinatal Association·1991

Primary immune response to blood group antigens in burned children.

Immunohematology·1991

Effective leukocyte removal from platelet preparations by centrifugation in a new pooling bag.

Transfusion·1987

Early events in lymphocyte activation as defined by three new monoclonal antibodies.

Journal of immunology (Baltimore, Md. : 1950)·1986

Therapeutic plasmapheresis and plasma exchange.

Critical reviews in clinical laboratory sciences·1986

Delayed hemolytic transfusion reaction caused by a primary immune response.

Transfusion·1982

Commentary: This Is Not a Drill.

Texas medicine·2021

Healthy Determination: Texas Physicians are Finding Better Ways to Address Their Patients' Social Determinants of Health.

Texas medicine·2021

Going Local: Accountable Health Organizations Could Help Combat Social Disparities at the Local Level.

Texas medicine·2021

Data Driven: Medicaid's Inspector General Focuses on Fraud Prevention, Not Just Prosecution.

Texas medicine·2021

Talk to Patients About: Vaccine Adverse Event Reporting System (VAERS).

Texas medicine·2021

Obstacles to Clear.

Texas medicine·2021

Tetracycline-loaded nanomotors target neutrophil activation and oxidative stress in acute lung injury.

iScience·2026

Self-reported side effects of tattooing: a cross-sectional study in the Swedish TABOO cohort.

BMJ public health·2026

Development of cecal volvulus after redo pancreas transplantation.

Journal of surgical case reports·2026

Primary Diffuse Large B-Cell Lymphoma of the External Auditory Canal with Extensive Local Extension: A Case Report and Literature Review.

Iranian journal of otorhinolaryngology·2026

Early Changes in the Neutrophil-to-Lymphocyte Ratio are Associated with Conversion Outcomes in Advanced Hepatocellular Carcinoma Treated with HAIC-Based Triple Therapy.

Journal of hepatocellular carcinoma·2026

Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy.

Research and practice in thrombosis and haemostasis·2026

Related Experiment Videos

Blood component therapy for cancer patients

Related Concept Videos

Use of red blood cells older than five days for neonatal transfusion.

Primary immune response to blood group antigens in burned children.

Effective leukocyte removal from platelet preparations by centrifugation in a new pooling bag.

Early events in lymphocyte activation as defined by three new monoclonal antibodies.

Therapeutic plasmapheresis and plasma exchange.

Delayed hemolytic transfusion reaction caused by a primary immune response.

Commentary: This Is Not a Drill.

Healthy Determination: Texas Physicians are Finding Better Ways to Address Their Patients' Social Determinants of Health.

Going Local: Accountable Health Organizations Could Help Combat Social Disparities at the Local Level.

Data Driven: Medicaid's Inspector General Focuses on Fraud Prevention, Not Just Prosecution.

Talk to Patients About: Vaccine Adverse Event Reporting System (VAERS).

Obstacles to Clear.

Tetracycline-loaded nanomotors target neutrophil activation and oxidative stress in acute lung injury.

Self-reported side effects of tattooing: a cross-sectional study in the Swedish TABOO cohort.

Development of cecal volvulus after redo pancreas transplantation.

Primary Diffuse Large B-Cell Lymphoma of the External Auditory Canal with Extensive Local Extension: A Case Report and Literature Review.

Early Changes in the Neutrophil-to-Lymphocyte Ratio are Associated with Conversion Outcomes in Advanced Hepatocellular Carcinoma Treated with HAIC-Based Triple Therapy.

Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy.

Related Experiment Videos

Blood component therapy for cancer patients

Related Concept Videos

Related Articles